Plasminogen activator inhibitor-1 (PAI-1) like the best mortality predictor of in the COVID-19-associated pneumonia

Acquired Hemophilia A after SARS-CoV-2 Infection: A Case Report and an Updated Systematic Review

“…Endothelial damage impairs antithrombotic function with the imbalanced release of tissue factor and tissue factor pathway inhibitor [ 33 ], in addition to the production and release of von Willebrand Factor and cleavage of ultra large von Willebrand Factor by ADAMTS13 [ 34 ]. The production and release of tissue plasminogen activator (t-PA) and the decreased production of plasminogen activator inhibitor (PAI-1) lead to impaired fibrinolysis [ 35 ]. With the disruption of the endothelial glycocalyx layer, the loss of vasodilation and vasoconstriction, together with the microvascular clot formation, leads to impaired organ perfusion and to organ dysfunction and multiple organ failure [ 35 ].…”

“…The production and release of tissue plasminogen activator (t-PA) and the decreased production of plasminogen activator inhibitor (PAI-1) lead to impaired fibrinolysis [ 35 ]. With the disruption of the endothelial glycocalyx layer, the loss of vasodilation and vasoconstriction, together with the microvascular clot formation, leads to impaired organ perfusion and to organ dysfunction and multiple organ failure [ 35 ].…”

ERS International Congress 2022: highlights from the Respiratory Clinical Care and Physiology Assembly

“…They showed that the risk of mortality was 219-fold higher [95% confidence interval: 8-6224] in patients with increased PAI-1 on admission above 20.6 ng/L, compared to the others, with good sensitivity and specificity of this cut level (area under the receiver operating characteristic (ROC) curve: 0.78). Furthermore, when analysing autopsies, they showed that defects in fibrinolysis may play a role in thrombogenesis in COVID-19 patients [12]. In a previous study conducted in the USA, the investigators had also shown that elevated PAI-1 level was associated with hospitalisation due to COVID-19 and worse respiratory status.…”

“…One such possible biomarker is the plasminogen activator inhibitor-1 (PAI-1). B ielosludtseva and P ertseva [ 12 ] (Dnipro, Ukraine) investigated the potential of PAI-1 to predict prognosis and risk of mortality in 85 patients admitted with COVID-19 pneumonia (40 moderate, 25 severe, 20 critical). They showed that the risk of mortality was 219-fold higher (95% CI 8–6224) in patients with increased PAI-1 on admission above 20.6 ng·L −1 , compared to the others, with good sensitivity and specificity of this cut-off level (area under the receiver operating characteristic (ROC) curve 0.78).…”